TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29028966
Drug: Any recent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Any recent drug use
Study: 29029122
Drug: HZ/su (adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZ/su (adjuvanted herpes zoster subunit vaccine), 2 doses 2 months apart
Study: 29029122
Drug: HZ/su (adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZ/su (adjuvanted herpes zoster subunit vaccine)
Study: 29029127
Drug: GBS vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS vaccine (0.5, 2.5, or 5.0 μg of each of 3 CRM197-glycoconjugates)
Study: 29029127
Drug: GBS vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS vaccine
Study: 29030503
Drug: Blended therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended therapy combining face-to-face problem solving and a smartphone app
Study: 29031861
Drug: Treatment team-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment team-directed nutrition (TTDN)
Study: 29033369
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of C. symbiosum and FIT
Study: 29033369
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all markers (C. symbiosum, F. nucleatum, FIT, CEA)
Study: 29033896
Drug: KDT501 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KDT501 treatment for 28 days
Study: 29034366
Drug: Sorafenib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib combined with chemotherapy
Study: 29035939
Drug: 40-mg olmesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-mg olmesartan
Study: 29036345
Drug: Cabozantinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (100 mg/day)
Study: 29037983
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan at 5.4 mg/kg or greater
Study: 29038072
Drug: Levonorgestrel 52
Normalized name: LEVONORGESTREL 52MG INSERT INTRAUTERINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 52 mg IUS
Study: 29038184
Drug: Participatory action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participatory action research (PAR) approach to improve antibiotic prescribing quality
Study: 29038184
Drug: Process evaluation
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Process evaluation and theory building on improving antibiotic prescribing
Study: 29038338
Drug: CD19-targeted chimeric
Normalized name: Autologous anti-CD20/CD19-targeting tandem CAR T cells MB-CART2019.1
DrugBank: Zamtocabtagene autoleucel (DB18764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-targeted chimeric antigen receptor-modified T (CAR-T)-cell immunotherapy
Study: 29038891
Drug: Cyanocobalamin 1.5
Normalized name: cyanocobalamin 1.5 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyanocobalamin 1.5 µg
Study: 29038891
Drug: Cyanocobalamin 3
Normalized name: CYANOCOBALAMIN 30MCG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyanocobalamin 3 µg
Study: 29038891
Drug: Cyanocobalamin 6
Normalized name: cyanocobalamin 6 MG Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyanocobalamin 6 µg
Study: 29038891
Drug: Cyanocobalamin 9
Normalized name: VITAMIN A ACETATE 2500 [iU] / ASCORBIC ACID 100 mg / CHOLECALCIFEROL 600 [iU] / .ALPHA.-TOCOPHEROL, DL- 30 [iU] / THIAMINE HYDROCHLORIDE 1.5 mg / RIBOFLAVIN 1 mg / NIACINAMIDE 20 mg / PYRIDOXINE HYDROCHLORIDE 2 mg / LEVOMEFOLATE GLUCOSAMINE 216 ug / CYANOCOBALAMIN 9 ug / BIOTIN 45 ug / CALCIUM PANTOTHENATE 10 mg / IRON PENTACARBONYL 9 mg / ZINC OXIDE 12 mg / COPPER 1 mg / SODIUM FLUORIDE 0.25 mg ORAL TABLET, CHEWABLE [Quflora FE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyanocobalamin 9 µg (normal status)
Study: 29038891
Drug: Cyanocobalamin (6
Normalized name: Cyanocobalamin (60Co)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyanocobalamin (6 µg) vs 3 µg (low status)
Study: 29038891
Drug: Cyanocobalamin (6
Normalized name: Cyanocobalamin (60Co)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyanocobalamin (6 µg) vs 9 µg (normal status)
Study: 29040433
Drug: Epinephrine administration
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine administration
Study: 29040638
Drug: Serum progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Serum progesterone < 9.2 ng/ml
Study: 29040638
Drug: Serum progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Serum progesterone ≥ 9.2 ng/ml
Study: 29040638
Drug: Logistic regression
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Logistic regression analysis for serum P < 9.2 ng/ml
Study: 29041979
Drug: Anti-tumor necrosis
Normalized name: G 1 (anti-tumor agent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tumor necrosis factor (anti-TNF) treatment with or without MTX
Study: 29042364
Drug: Adoptive immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive immunotherapy with genetically modified T cells
Study: 29043014
Drug: Lanadelumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanadelumab (300 mg subcutaneously) administered every 2 weeks after an initial dose on Day 0 and after the first confirmed angioedema attack for rollover patients.
Study: 29043014
Drug: Lanadelumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanadelumab (300 mg subcutaneously) administered every 2 weeks for non-rollover patients regardless of the first attack.
Study: 29045037
Drug: Anti-ficolin-2 antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-ficolin-2 antibodies in SLE patients
Study: 29045037
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anti-ficolin-2, anti-ficolin-3, and anti-C1q
Study: 29045540
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg i.v. Q3weeks until disease progression
Study: 29045543
Drug: Lapatinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib and trastuzumab (and hormonal therapy if HR-positive) for 18 weeks
Study: 29045739
Drug: 0.50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg/kg bodyweight ketamine administered once i.v.
Study: 29046319
Drug: Intravenous Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Fentanyl
Study: 29047411
Drug: Lactate level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate level > 1.5 mmol/L
Study: 29047411
Drug: Mildly elevated
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mildly elevated lactate levels (1-2 mmol/L)
Study: 29049861
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg) followed by Misoprostol (800 μg buccal) after 24 hours
Study: 29051021
Drug: Nilotinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib (200 mg dose identified as maximum tolerated dose)
Study: 29051021
Drug: Nilotinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib (200 mg dose)
Study: 29051021
Drug: Pretreatment anti-PDGFRA
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment anti-PDGFRA antibody levels ≥ .150 optical density
Study: 29051134
Drug: Video-based telerehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-based telerehabilitation intervention (8 weekly, 1-hour sessions)
Study: 29053802
Drug: DHA (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (800 mg, algal oil) daily from 26 weeks to term
Study: 29053802
Drug: Placebo (corn/soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (corn/soy oil) daily from 26 weeks to term
Study: 29055637
Drug: Normal Glucose
Normalized name: Normal Glucose Control Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Glucose Metabolism (NGM)
Study: 29055736
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT lung cancer screening
Study: 29056570
Drug: AZD3759 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3759 at 200 mg twice a day
Study: 29056570
Drug: AZD3759 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3759 at 300 mg twice a day
Study: 29057117
Drug: Triple fixed-combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple fixed-combination bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% (TFC)
Study: 29057117
Drug: Dual fixed-combination
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual fixed-combination brimonidine 0.2%/timolol 0.5% (DFC)
Study: 29058601
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of meropenem
Study: 29058816
Drug: Oral bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral bosutinib (100 mg × 5)
Study: 29058816
Drug: Intravenous bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous bosutinib (120 mg in approximately 240 mL over 1 hour)
Study: 29062240
Drug: Oliceridine regimen
Normalized name: Oliceridine
DrugBank: Oliceridine (DB14881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oliceridine regimen A (1.5/0.10 mg)
Study: 29062240
Drug: Oliceridine regimen
Normalized name: Oliceridine
DrugBank: Oliceridine (DB14881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oliceridine regimen B (1.5/0.35 mg)
Study: 29062240
Drug: Morphine (4.0/1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (4.0/1.0 mg)
Study: 29064349
Drug: Bosentan monotherapy
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan monotherapy for 16 weeks
Study: 29064927
Drug: Rectal distension
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal distension stimulations in patients with IBS
Study: 29064927
Drug: Rectal distension
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal distension stimulations in healthy controls
Study: 29065747
Drug: Intravenous melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous melphalan
Study: 29065865
Drug: Exenatide 5
Normalized name: EXENATIDE 5MCG/DOSE 1.2ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 5 to 10 μg twice a day for 20 weeks
Study: 29066505
Drug: Pan-AKT Inhibitor
Normalized name: Pan-raf inhibitor lxh254
DrugBank: Naporafenib (DB18865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pan-AKT Inhibitor AZD5363
Study: 29066590
Drug: Home Pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home Pulmonary Rehabilitation (PR) program including a computer tablet, activity monitor, and oximeter, with 12 min of walking and 6 full-body exercises, completed 6 days/week, plus weekly telephone calls with the PR health coach.
Study: 29067298
Drug: Bexarotene (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexarotene (oral administration for 3 days)
Study: 29067298
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral administration for 3 days)
Study: 29067304
Drug: Aducanumab (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aducanumab (0.3, 1, 3, 10, 20, 30, and 60 mg/kg)
Study: 29067332
Drug: UB-311 (synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: UB-311 (synthetic peptide vaccine)
Study: 29067643
Drug: Gedatolisib (PF-05212384)
Normalized name: Gedatolisib
DrugBank: Gedatolisib (DB11896)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gedatolisib (PF-05212384) with Irinotecan 180 mg/m
Study: 29068794
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (50-300 mg/day) as monotherapy or adjunctive therapy
Study: 29068794
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (higher than recommended doses)
Study: 29068794
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR as adjunctive therapy to antidepressants
Study: 29069114
Drug: Concomitant calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant calcium channel blocker (CCB) plus antipsychotic (AP) therapy
Study: 29069114
Drug: Antipsychotic (AP)
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic (AP) therapy alone
Study: 29070010
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg twice-daily for 1 year
Study: 29070480
Drug: Internet-delivered dialectical
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered dialectical behavior therapy (DBT) skills training, 8-week intervention
Study: 29070939
Drug: palucorcel (CNTO
Approvals — FDA: no, EMA: no, PMDA: no
Description: palucorcel (CNTO 2476) administered subretinally at a targeted dose of 3.0×10
Study: 29071072
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal therapy (HFNT) during exercise tests
Study: 29071087
Drug: DS-8500a 10
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8500a 10 mg
Study: 29071091
Drug: RenalGuard system
Approvals — FDA: no, EMA: no, PMDA: no
Description: RenalGuard system with weight-adjusted intravenous furosemide
Study: 29072772
Drug: Bosutinib treatment
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib treatment in CP2L cohort
Study: 29072772
Drug: Bosutinib treatment
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib treatment in CP3L cohort
Study: 29073362
Drug: Early implant
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early implant placement with simultaneous contour augmentation through guided bone regeneration with a 2-layer composite graft
Study: 29073584
Drug: Vismodegib 150
Normalized name: vismodegib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib 150 mg/d
Study: 29074501
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg/d until progression or intolerance
Study: 29075620
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPIs), specific dosage and duration not mentioned.
Study: 29075855
Drug: Depatuxizumab mafodotin
Normalized name: Depatuxizumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depatuxizumab mafodotin (depatux-m) monotherapy at 1.25 mg/kg intravenously every 2 weeks
Study: 29077645
Drug: Diet Rite
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet Rite Cola, sweetened with 68-mg sucralose and 41-mg ace-K
Study: 29077963
Drug: Movement System
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movement System Impairment-Based Classification Treatment
Study: 29078273
Drug: Bevacizumab (anti-VEGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (anti-VEGF drug)
Study: 29078773
Drug: Anti-malarial treatment
Normalized name: malarial plasmodium group immunoserum rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-malarial treatment
Study: 29079633
Drug: Severe persistent
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe persistent hyponatraemia (serum sodium <130 mmol/L)
Study: 29079658
Drug: High-sensitivity cardiac
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity cardiac troponin I (hs-cTnI) measurements using Abbott assay, sex-specific 99th percentiles (women, 16 ng/L; men, 34 ng/L)
Study: 29079987
Drug: Novel DGP
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel DGP treatment (specifics not provided)
Study: 29080061
Drug: Chemotherapy (CTh+)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CTh+)
Study: 29080915
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg triamcinolone
Study: 29080970
Drug: Ibrutinib 1680
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib 1680 mg
Study: 29081368
Drug: JE-CV (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-CV (single dose)
Study: 29082335
Drug: Daily 12-lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 12-lead ECG once daily for 5 days
Study: 29082650
Drug: Telbivudine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine therapy throughout pregnancy
Study: 29084869
Drug: Early intravenous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intravenous immunoglobulin treatment
Study: 29086392
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydralazine and isosorbide dinitrate (Hy+ISDN)
Study: 29087741
Drug: Long-term supplemental
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term supplemental oxygen treatment
Study: 29089191
Drug: Quadrivalent live
Normalized name: influenza vaccine quadrivalent live 2015-2016 (2 yrs-49 yrs) 10exp6.5-7.5 FF unit/0.2 mL NASAL NASAL SPRAY SYRINGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent live attenuated influenza vaccine (LAIV4) or inactivated influenza vaccine (IIV4)
Study: 29090343
Drug: Non-intensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-intensive treatment or best supportive care
Study: 29091557
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of adeno-associated virus serotype 9 carrying SMN complementary DNA
Study: 29091557
Drug: High-dose cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cohort of adeno-associated virus serotype 9
Study: 29092017
Drug: Conservative compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conservative compression treatment
Study: 29093819
Drug: Dialectical Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behaviour Therapy (DBT) adapted for Adolescents
Study: 29095983
Drug: Metformin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1 g twice daily) for 9.4 to 13.7 weeks
Study: 29096647
Drug: Access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access to HCV medical treatment for HCV-positive patients
Study: 29096668
Drug: Lenalidomide plus
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide plus other treatment
Study: 29096668
Drug: Overall response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Overall response rate to lenalidomide-based therapy
Study: 29096668
Drug: Treatment-emergent adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent adverse events after lenalidomide-containing therapy
Study: 29096670
Drug: E/C/F/TDF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: E/C/F/TDF plus darunavir 800 mg daily
Study: 29096790
Drug: Mean on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mean on-treatment BP (systolic and diastolic)
Study: 29097417
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with HIV in care with viral loads >1500 copies/mL
Study: 29097417
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with HIV in care with high viral loads and concurrent risk behaviour
Study: 29098088
Drug: Dilute (3%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilute (3%) povidone-iodine solution through a low-pressure pulsatile device
Study: 29098088
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution through a bulb syringe
Study: 29098299
Drug: Bioabsorbable steroid-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioabsorbable steroid-releasing implant (370 µg of mometasone furoate) placed in the frontal sinus ostia (FSO) after endoscopic sinus surgery (ESS)
Study: 29098299
Drug: Bioabsorbable steroid-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioabsorbable steroid-releasing implant
Study: 29099942
Drug: High-specific-activity I-131
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-specific-activity I-131 meta-iodobenzylguanidine (MIBG) therapy at a maximum tolerated dose (MTD) of 296 MBq/kg.
Study: 29099942
Drug: High-specific-activity I-131
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-specific-activity I-131 MIBG therapy
Study: 31334596
Drug: Ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg every 3 weeks
Study: 31334596
Drug: Ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 10 mg/kg every 3 weeks
Study: 29100412
Drug: Bromocriptine (7.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (7.5mg daily) added to spironolactone